Start-ups & Opportunities
Oxford biotech OMass raises $310 million for rare hormone disorder drugs
Oxford spin-out OMass Therapeutics raised $310 million in a Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings on October 15, 2026.
16 Oct 2026, 18:51 IST